CCC
AMGN icon

Crescent Capital Consulting’s Amgen AMGN Stock Holding History

Crescent Capital Consulting’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$34K Buy
150
+4
+3% +$844 0.01% 321
2021
Q3 		$31K Hold
146
– – 0.01% 345
2021
Q2 		$36K Sell
146
-11
-7% -$2.71K 0.01% 298
2021
Q1 		$39K Buy
157
+11
+8% +$2.63K 0.01% 298
2020
Q4 		$34K Buy
+146
New +$33.7K 0.01% 277

Other funds holding AMGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Crescent Capital Consulting's AMGN Position: Q4 2021 in Review

Crescent Capital Consulting increased its Amgen (AMGN) stake by 2.7% in Q4 2021, buying an estimated $844 and bringing the position to 150 shares worth $34K. The position accounts for 0.01% of the portfolio, ranked #321.

Crescent Capital Consulting first reported a position in AMGN in Q4 2020 and has held it in 5 quarters since. The position peaked at $39K in Q1 2021. 2,293 funds tracked by Wall St. Rank hold AMGN as of Q4 2021.

  • Crescent Capital Consulting held 150 shares of Amgen worth $34K as of Q4 2021.
  • Crescent Capital Consulting bought 4 Amgen shares in Q4 2021, an estimated $844.
  • Amgen made up 0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #321 holding.
  • Crescent Capital Consulting first reported a position in Amgen in Q4 2020 and has held it in 5 quarters since.
  • Crescent Capital Consulting's Amgen position peaked at $39K in Q1 2021.
  • 2,293 funds tracked by Wall St. Rank held Amgen as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.